The American Society of Health-System Pharmacists and the ASHP Foundation have released their 13th annual Pharmacy Forecast, a comprehensive guide designed to help pharmacy leaders navigate the evolving healthcare landscape. 

The FDA has recalled more than 233,000 bottles of antidepressant duloxetine, sold by Rising Pharmaceuticals, due to a potential cancer risk. 

A new report from the Institute for Clinical and Economic Review showed that recent unsupported price hikes for top-selling drugs contributed to $815 million to U.S. medical spending in 2023. 

The FDA has issued a safety warning about the use of Ocaliva in patients with primary biliary cholangitis, specifically those who do not have cirrhosis of the liver. 

Gene editing company Editas Medicine will reduce its workforce by 65% over the next six months as it focuses on in vivo CRISPR-edited medicines. 

Historically viewed as cost centers, hospitals and health systems are increasingly identifying their pharmacy departments as "revenue engines," according to Vizient. 

The FDA has placed a hold on all clinical studies of vaccines for respiratory syncytial virus in infants due to safety concerns following a trial involving two mRNA-based vaccine candidates from Moderna. 

HHS has extended liability protections for COVID-19 vaccines, treatments and diagnostic tests under the Public Readiness and Emergency Preparedness Act through Dec. 31, 2029.

The introduction of ultra high-cost drugs, such as gene and cell therapies, is set to reshape pharmacy practices, according to a forecast published in the American Journal of Health-System Pharmacy from the American Society of Health-System Pharmacists and ASHP Foundation,…

Eli Lilly will launch studies to investigate whether its weight loss medications can help control addictive behaviors such as smoking and alcohol and drug abuse, CEO Dave Ricks revealed in a Dec. 10 interview, Bloomberg reported.